Eli Lilly has now submitted a new drug application (NDA) for GLP-1RA orforglipron to the FDA for use in adults with obesity.

Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

Anova Enterprises has launched the AnovaOS SaaS platform, a new AI-based patient matching solution for clinical trials.

Rezolute still has another Phase III trial of ersodetug in progress to rely upon, with data expected in H2 2026.

FL is the most common indolent form of B-cell NHL. Credit: Motortion Films/Shutterstock.com. At the American Society of Hematology (ASH) Annual Meeting, held on 6-9 December, results from the global, ...

Immunome’s acquired gamma secretase inhibitor, varegacestat, has demonstrated its efficacy and tolerability in a Phase III study, meaning the company will now file for the drug’s approval with the FDA ...

In earlier Phase I/II data, microdystrophin concentration ranged from 20% to 122% after the pivotal dose. Credit: Sai Thaw Kyar / Shutterstock.com. REGENXBIO has concluded enrolment of subjects in the ...

The trial will enrol 300 chronic low back pain patients with inflammatory degenerative disc disease of less than five years duration. Credit: Anatoliy Cherkas / Shutterstock. Australia-based Mesoblast ...

Almost three decades ago, the FDA allowed women back into clinical research to participate as subjects, but the representation of females remains an issue, especially in Phase I trials. A recent study ...